Abstract
Effective medical therapy for men with clinical manifestations ultimately resulting from the histologic process of benign prostatic hyperplasia (BPH) has changed the practice of urology. For example, despite an aging population, the number of transurethral prostatectomies performed in the United States has fallen from a peak number of 379,000 in 1987 to 145,000 in 1996. This decline has occurred to a large degree because clinicians usually try a course of medical therapy first before resorting to surgical treatment. Also, for better or worse, the availability of medical therapy now allows primary-care physicians to treat men with clinical manifestations of BPH before referring them to a urologist. Effective use of medical therapy for men with symptoms attributed to BPH is a key skill in office urology.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Selected Reading
Andersen JT, Nickel JC, Marshall VR, et al. (1997) Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 49: 839–845.
Barry MJ, Fowler FJ, O’Leary MP, et al. (1992) The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 148: 1549–1557.
Boyle P, Gould AL, Roehrborn CG (1996) Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 48: 398–405.
Buzelin JM, Fonteyne E, Kontturi M, et al. (1997) Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). Br J Urol 80: 597–605.
Gormley GJ, Stoner E, Bruskewitz RC (1992) The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327: 1185–1191.
Guess HA, Gormley GJ, Stoner E, et al. (1996) The effect of finasteride on prostate specific antigen: review of available data. J Urol 155: 3–9.
Jardin A, Bensadoun H, Delauche-Cavillier MC (1991) Alfuzosin for treatment of benign prostatic hypertrophy. Lancet 337: 1457–1461.
Kirby RS, Pool JL (1997) Alpha adrenoreceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future. Br J Urol 80: 521–532.
Lepor H, Williford WO, Barry MJ, et al. (1996) The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335: 533–539.
Lepor H, Williford WO, Barry MJ, et al. (1998) The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J Urol 160: 1358–1367.
McConnell JD, Bruskewitz RC, Walsh P, et al. (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338: 557–563.
Narayan P, Tewari A (1998) Overview of alpha-blocker therapy for benign prostatic hyperplasia. Urology 51, (Suppl. 4A), 38–45.
Narayan P, Tewari A, Members of United States 93–01 Study Group. (1998) A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 160: 1701–1706.
Roehrborn CG, Siegel RL (1996) Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. Urology 48: 406–415.
Roehrborn CG, Oesterling JE, Auerbach S, et al. (1996) The hytrin community assessment trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. Urology 47: 159–168.
Roehrborn CG, Girman CJ, Rhodes T, et al. (1997) Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology 49: 548–557.
Roehrborn CG, McConnell JD, Lieber M, et al. (1999) Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 53: 473–480.
Roehrborn CG, Boyle P, Gould AL, Waldstreicher J (1999) Serum prostate specific antigen (PSA) as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 53: 581–589.
Wilt TJ, Ishani A, Stark G, et al. (1998) Saw palmetto extracts for treatment of benign prostatic hyperplasia. JAMA 280: 1604–1609.
Witjes WPJ, Rosier PFWM, Caris CTM, et al. (1997) Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis. Urology 49: 197–206.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Barry, M.J., Roehrborn, C. (2001). Medical Management of Benign Prostatic Obstruction. In: Kursh, E.D., Ulchaker, J.C. (eds) Office Urology. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-010-0_18
Download citation
DOI: https://doi.org/10.1007/978-1-59259-010-0_18
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-188-2
Online ISBN: 978-1-59259-010-0
eBook Packages: Springer Book Archive